|
|
|
By Shubhranshu Gupta, Ph.D., cell therapy expert | The second part of a discussion on closed-loop systems explores the CDMO and equipment landscape for scaling automated closed loop cell therapy manufacturing systems. | |
|
|
| Rapid, Simple Aggregate Removal Of mAbs Using Competitive Binding | Poster | By Indraneel Sanyal, Nuresh Manukonda, Ankitha Hirematha, and Mukesh Dakua, Aragen | To ensure the safety, efficacy, and stability of monoclonal antibody therapies, it is crucial to understand the factors driving aggregation and implement effective strategies to mitigate its impact. |
|
|
|
|
|
| Getting To The Heart Of CDMO Tech Transfer Excellence | Article | Bora Pharmaceuticals | Discover key factors that drive a seamless and efficient technology transfer. Learn how a culture of technical expertise, customer focus, and operational flexibility is crucial to CDMO success. |
|
|
|
|
|
|
|
Connect With Bioprocess Online: |
|
|
|